121860 20260217205449.0 doi 10.3390/cancers15020329 sideral 132236 ART-2023-132236 eng Gascón-Ruiz, Marta (orcid)0000-0002-6811-6654 A Subset of PD-1-Expressing CD56bright NK Cells Identifies Patients with Good Response to Immune Checkpoint Inhibitors in Lung Cancer 2023 Access copy available to the general public Unrestricted (1) Despite the effectiveness of immune checkpoint inhibitors (ICIs) in lung cancer, there is a lack of knowledge about predictive biomarkers. The objective of our study is to analyze different subsets of T-lymphocytes and natural killer (NK) cells as predictive biomarkers in a cohort of patients with nonsmall cell lung cancer (NSCLC) treated with ICI. (2) This is an observational, prospective study with 55 NSCLC patients treated with ICI. A total of 43 T and NK cell subsets are analyzed in peripheral blood, including the main markers of exhaustion, differentiation, memory, activation, and inhibition. (3) Regarding the descriptive data, Granzyme B+CD4+ Treg lymphocytes stand out (median 17.4%), and within the NK populations, most patients presented cytotoxic NK cells (CD56+CD3−CD16+GranzymeB+; median 94.8%), and about half of them have highly differentiated adaptive-like NK cells (CD56+CD3−CD16+CD57+ (mean 59.8%). A statistically significant difference was observed between the expression of PD1 within the CD56bright NK cell subpopulation (CD56+CD3−CD16−PD-1+) (p = 0.047) and a better OS. (4) Circulating immune cell subpopulations are promising prognostic biomarkers for ICI. Pending on validation with a larger sample, here we provide an analysis of the major circulating T and NK cell subsets involved in cancer immunity, with promising results despite a small sample size. info:eu-repo/grantAgreement/ES/AEI/PID2020-113963RB-I00 info:eu-repo/grantAgreement/ES/AEI/PTA2019-016739-I info:eu-repo/grantAgreement/ES/DGA/B29-20R info:eu-repo/grantAgreement/ES/ISCIII/CB21-13-00087 info:eu-repo/semantics/openAccess by https://creativecommons.org/licenses/by/4.0/deed.es 4.5 2023 ONCOLOGY 78 / 322 = 0.242 2023 Q1 T1 1.391 2023 Oncology 2023 Q1 Cancer Research 2023 Q2 8.0 2023 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Ramírez-Labrada, Ariel (orcid)0000-0002-3888-7036 Lastra, Rodrigo Martínez-Lostao, Luis Universidad de Zaragoza (orcid)0000-0003-3043-147X Paño-Pardo, J. Ramón Universidad de Zaragoza (orcid)0000-0002-9600-8116 Sesma, Andrea Zapata-García, María Moratiel, Alba Quílez, Elisa Torres-Ramón, Irene (orcid)0000-0003-3387-0558 Yubero, Alfonso Domingo, María Pilar (orcid)0000-0002-7071-2201 Esteban, Patricia Gálvez, Eva M. (orcid)0000-0001-6928-5516 Pardo, Julián Universidad de Zaragoza (orcid)0000-0003-0154-0730 Isla, Dolores 1011 566 Universidad de Zaragoza Dpto. Microb.Ped.Radio.Sal.Pú. Área Inmunología 1007 610 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Area Medicina 15, 2 (2023), 329 [19 pp.] Cancers Cancers 2072-6694 1959841 http://zaguan.unizar.es/record/121860/files/texto_completo.pdf Versión publicada 2862357 http://zaguan.unizar.es/record/121860/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:121860 articulos driver 2026-02-17-20:18:36 ARTICLE